1. Effect of fenoldopam in dogs with spontaneous renal insufficiency
- Author
-
Kristen Karpinski, P. Dennis DePalma, Robin Goldstein, marty Hyneck, David P. Brooks, Martin DiCristo, and Paul F. Koster
- Subjects
Male ,medicine.medical_specialty ,Kidney Cortex ,Fenoldopam ,Renal cortex ,Dopamine Agents ,Urology ,Extraction ratio ,Administration, Oral ,PAH clearance ,In Vitro Techniques ,urologic and male genital diseases ,Dopamine agonist ,Dogs ,Oral administration ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology ,business.industry ,medicine.anatomical_structure ,Endocrinology ,Renal blood flow ,Creatinine ,Injections, Intravenous ,Organic anion transport ,Kidney Failure, Chronic ,Female ,p-Aminohippuric Acid ,2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine ,business ,medicine.drug - Abstract
Fenoldopam administration orally or i.v. resulted in significant increases in paraaminohippuric acid (PAH) clearance in both four control dogs and four dogs with chronic renal failure. Oral fenoldopam resulted in significant plasma levels of fenoldopam sulfate metabolites. One metabolite, fenoldopam-8-sulfate, a potential inhibitor of organic anion transport, did not depress renal cortical slice accumulation of PAH. The data therefore indicate that in dogs with chronic renal failure, PAH clearance after fenoldopam administration is a reliable measure of renal plasma flow, and fenoldopam can result in an increase in renal plasma flow.
- Published
- 1990